<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748578</url>
  </required_header>
  <id_info>
    <org_study_id>EBI-005-1</org_study_id>
    <nct_id>NCT01748578</nct_id>
  </id_info>
  <brief_title>Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects</brief_title>
  <acronym>EBI-005-1</acronym>
  <official_title>A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eleven Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eleven Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First-In-Human (FIH) study to assess the safety and tolerability of ocular&#xD;
      administration of EBI-005 in healthy volunteers. Additionally, the PK and immunogenicity of&#xD;
      EBI-005 will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned dose levels are 5 mg/mL EBI-005 (Group 1) and 20 mg/mL EBI-005 (Group 2).&#xD;
&#xD;
      A total of 8 subjects will be dosed in each group with subjects randomized in a ratio of 6:2,&#xD;
      EBI-005:placebo. Treatment administration in Group 2 will proceed following a review of&#xD;
      safety data from Group 1. In both groups, subjects randomized to active treatment will&#xD;
      receive EBI-005 in the right eye and placebo in the left eye. Subjects randomized to placebo&#xD;
      will receive placebo in each eye.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in ocular safety measurements.</measure>
    <time_frame>1 week</time_frame>
    <description>Determined by best corrected visual acuity, slit lamp examination, measurement of intraocularpressure (IOP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA based assay to determine Pharmacokinetics for the evaluation of systemic exposure of EBI-005 in healthy volunteers.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA based assay to determine Immunogenicity for the evaluation of systemic exposure of EBI-005 in healthy volunteers.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>EBI-005-1 5mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBI-005-1 20 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EBI-005-1</intervention_name>
    <description>EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo</description>
    <arm_group_label>EBI-005-1 20 mg/mL</arm_group_label>
    <arm_group_label>EBI-005-1 5mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EBI-005-1 Placebo</intervention_name>
    <arm_group_label>EBI-005-1 20 mg/mL</arm_group_label>
    <arm_group_label>EBI-005-1 5mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males and/or females between the ages of 18 and 65 years&#xD;
&#xD;
          -  Medically healthy&#xD;
&#xD;
          -  Best correction vision of greater than or equal to 20/40 in each eye&#xD;
&#xD;
          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to&#xD;
             dosing&#xD;
&#xD;
          -  Tolerate topical administration to eye&#xD;
&#xD;
          -  Signed and dated, Institutional Review Board (IRB) approved informed consent form&#xD;
             (ICF) prior to any protocol-specific screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic (including&#xD;
             sensitive skin on the face), neurological, or psychiatric disease, or any other&#xD;
             clinically significant disease not deemed acceptable by the PI&#xD;
&#xD;
          -  History of any primary malignancy, with the exception of basal cell or squamous cell&#xD;
             carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively&#xD;
             treated and with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  Occurrence of active seasonal allergies including ocular allergies (e.g.; annual hay&#xD;
             fever)&#xD;
&#xD;
          -  Abnormalities following ophthalmological examination: abnormality of the cornea,&#xD;
             evidence of ocular inflammation (dry eyes, blepharitis, allergic conjunctivitis,&#xD;
             iritis, and uveitis), glaucoma, and optic neuropathy&#xD;
&#xD;
          -  Subjects with a history of laser refractive surgery (laser assisted stromal in-situ&#xD;
             keratomileusis [LASIK], photorefractive keratectomy [PRK]), radial keratotomy (RK),&#xD;
             corneal transplantation, dry eyes, or radiotherapy to the eyes&#xD;
&#xD;
          -  Use of contact lenses currently or within the past one year&#xD;
&#xD;
          -  Positive urine drug/alcohol or cotinine testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Goldstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eleven Biotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Interleukin 1 Receptor Inhibitor</keyword>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

